Cardiovascular effects of the 1-(2" pyrimidyl)-5 piperonyl piperazine (ET 495).
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D001808:Blood Vessels / Q000187:drug effects*; D002302:Cardiac Output / Q000187:drug effects; D002415:Cats; D002490:Central Nervous System / Q000187:drug effects; D003714:Denervation; D004155:Diphenhydramine / Q000494:pharmacology; D004285:Dogs; D006145:Guanethidine / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006584:Hexamethonium Compounds / Q000494:pharmacology; D007545:Isoproterenol / Q000494:pharmacology; D010879:Piperazines / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000633:toxicity; D051381:Rats; D012039:Regional Blood Flow / Q000187:drug effects*; D012110:Reserpine / Q000494:pharmacology; D012119:Respiration / Q000187:drug effects; D013153:Splanchnic Nerves / Q000187:drug effects
D006584:Hexamethonium Compounds; D010879:Piperazines; D001285:Atropine; D012110:Reserpine; D004155:Diphenhydramine; D007545:Isoproterenol; D006145:Guanethidine